Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication (SAFARI)

This study has been completed.

Sponsor:

Bayer

ClinicalTrials.gov Identifier:

NCT01805531

First Posted: March 6, 2013

Last Update Posted: January 18, 2017

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.